In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

P2Y12-inhibitors in NSTEMI - old and new guidelines

Association for Acute CardioVascular Care webinar

16/02/2021 18:00 16/02/2021 19:00 Europe/Paris P2Y12-inhibitors in NSTEMI - old and new guidelines

Access event page

Association for Acute CardioVascular Care contact@escardio.org DD/MM/YYYY
Association for Acute CardioVascular Care
Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
Online
event

Summary

Join Prof. Stefan James, Prof. Steen Dalby Kristensen and Prof. Kurt Huber

Free for everyone

Focus on

Needs assessments:
The new ESC Clinical Practice Guidelines on NSTEMI recommend prasugrel over ticagrelor in ACS patients referred for percutaneous coronary intervention (PCI). At the same time these guidelines recommend using prasugrel only after the coronary anatomy is known and avoiding pre-cathlab use of P2Y12-inhibitors. Does this change clinical routine essentially, as :

  1. In many systems of ACS care, high-risk ACS patients cannot be treated by PCI with 24 hours of diagnosis and are therefore frequently pre-treated with ticagrelor or clopidogrel
  2. Patients with ACS but without indication for PCI frequently receive ticagrelor for a conservative strategy
  3. In ACS-patients with high or very high bleeding risk clopidogrel and in patients without increased bleeding risk ticagrelor have been tested for short DAPT (1-3 months) followed by P2Y12-inhibtor monotherapy with significant reduced bleeing hazards but similar ischemic outcome. No data are currently available for the use of prasugrel in this strategy.

 

Learning objectives

  • recognise the correct use of P2Y12-inhibtors (ticagrelor and prasugrel) in patients presenting with non-ST-elevation ACS
  • implement the new non-ST-elevation ACS guidelines in clinical practice
  • manage new indications for ticagrelor in ACS patients, namely as monotherapy after short duration of DAPT


Register now

Free for everyone

Faculty

Speakers

Stefan James Photo2.jpgProfessor Stefan James
Uppsala University
Uppsala, Sweden

Kristensen-Steen-Dalby-2016.jpgProfessor Steen Dalby Kristensen
Aarhus University Hospital
Aarhus, Denmark

Host

huber-kurt-2013.jpgProfessor Kurt Huber
Wilhelminen Hospital
Vienna, Austria

 

Session information

This webinar addresses general cardiologists but also cardiologists wishing to update their scientific knowledge on the topic.

During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.

An application has been made to the EACCME® for CME accreditation of this event.

Technical settings

The webinar is available on PC and tablets. The use of a smartphone is not recommended.

To answer the MCQs during the live, you must allow pop-up windows.

A high-speed Internet connection is required (minimum 2 Mbps).